What companies are CHB's competitors?

Global X China Biotech Innovation ETF (CHB)'s closest competitors are the companies in the same industry classification, listed in the Peers to Research table on this page. Click any peer ticker to open its full analysis.

How does CHB compare to its peers?

The peer comparison table on this page shows Global X China Biotech Innovation ETF (CHB) alongside each peer with price, market cap, and key valuation / dividend metrics aligned side-by-side. Use it to spot relative outliers within the same business model.

What sector does CHB operate in?

Global X China Biotech Innovation ETF (CHB) operates in the Asset Management industry within the Financial Services sector. Peers are drawn from this classification — companies with similar revenue mix, cost structure, and customer demand drivers.

CHB (Global X China Biotech Innovation ETF) is no longer actively trading.

This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

CHB

Global X China Biotech Innovation ETF

NASDAQ·Asset Management · Financial Services

$6.64$0.03−0.38%

Market cap$1.39M·Market closed·Feb 16 9:00 PM UTC

Frequently Asked Questions About CHB

What companies are CHB's competitors?: Global X China Biotech Innovation ETF (CHB)'s closest competitors are the companies in the same industry classification, listed in the Peers to Research table on this page. Click any peer ticker to open its full analysis.
How does CHB compare to its peers?: The peer comparison table on this page shows Global X China Biotech Innovation ETF (CHB) alongside each peer with price, market cap, and key valuation / dividend metrics aligned side-by-side. Use it to spot relative outliers within the same business model.
What sector does CHB operate in?: Global X China Biotech Innovation ETF (CHB) operates in the Asset Management industry within the Financial Services sector. Peers are drawn from this classification — companies with similar revenue mix, cost structure, and customer demand drivers.

CHB (Global X China Biotech Innovation ETF) is no longer actively trading.

CHB

Global X China Biotech Innovation ETF

NASDAQ·Asset Management · Financial Services

$6.64$0.03−0.38%

Market cap$1.39M·Market closed·Feb 16 9:00 PM UTC

Peers


WNDY	Global X Wind Energy ETF	$12.35	$1.7M
SDGS	Newday Sustainable Development Equity ETF	$19.72	$1.5M
NIWM	NightShares 2000 ETF	$27.82	$1.5M
KPOP	KPOP and Korean Entertainment ETF	$13.83	$1.4M
SMLE	Xtrackers S&P SmallCap 600 ESG ETF	$27.12	$1.4M
LJIM	Northern Lights Fund Trust IV - Long Cramer Tracker ETF	$26.56	$1.3M
TYNE	Direxion Nanotechnology ETF	$17.26	$1.3M
HOM	LifeGoal Home Down Payment Investment ETF	$8.64	$1.3M
GRZZ	Grizzle Growth ETF	$24.80	$1.2M
NXTV	Simplify NEXT Intangible Value Index ETF	$25.50	$1.2M

Frequently Asked Questions About CHB

What companies are CHB's competitors?: Global X China Biotech Innovation ETF (CHB)'s closest competitors are the companies in the same industry classification, listed in the Peers to Research table on this page. Click any peer ticker to open its full analysis.
How does CHB compare to its peers?: The peer comparison table on this page shows Global X China Biotech Innovation ETF (CHB) alongside each peer with price, market cap, and key valuation / dividend metrics aligned side-by-side. Use it to spot relative outliers within the same business model.
What sector does CHB operate in?: Global X China Biotech Innovation ETF (CHB) operates in the Asset Management industry within the Financial Services sector. Peers are drawn from this classification — companies with similar revenue mix, cost structure, and customer demand drivers.